B
Bluebird bio
Integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing
At a glance
- Founded
- 1993
- Headquarters
- Cambridge, United States
- Listing
- IPO 2013
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later12 investors entered at this stage
Third Rock Ventures- SVSanofi Ventures
- FPForbion Capital Partners
- CMCalifornia Institute for Regenerative Medicine
- TSTVM Capital Life Science
- TMTechno Venture Management
ARCH Venture Partners
RA Capital Management- MTMassachusetts Institute of Technology
- DPDeerfield Partners
- SBSanofi-Genzyme BioVentures
- WIWhitehead Institute
Source: Dealroom Talent Intelligence.
Alumni founders
Former Bluebird bio employees who went on to found companies, sorted by Dealroom signal score.
UBUmoja BiopharmaEst. 2019
Andy ScharenbergUnited States
KTKelonia TherapeuticsEst. 2020
Kevin FriedmanUnited States
Ankit KumarUnited States
GBGeneration BioEst. 2016
ONOncorusEst. 2015
Cyrus MozayeniUnited StatesGlobal footprint
team presence
across markets
Patents
43 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bluebird bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bluebird bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.